The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 3 of 63 results
Sort by date: Descending
Encores: Not included
Schizophrenia
AMCP 2025 POSTER
Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Initiating Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane,1 Regina Grebla,2 Michael J. Doane,2 Andrea B. Barthel,3 Chenxue Liang,3 Zhengfan Wang,3 Elizabeth S. Nagelhout,3 Lauren N. Strand2

View poster
Listen to Audio Abstract
0:00 0:00
Schizophrenia
Bipolar Disorder
Schizophrenia
SIRS 2025 POSTER
Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Martin Dunbar, PhD,2 Alexandra Lovett, MD,2 David McDonnell, MD,3 Christoph U. Correll, MD4-7

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia
Bipolar Disorder
AACAP 2024 POSTER
Olanzapine and Samidorphan in Pediatric Patients With Bipolar I Disorder: Pharmacokinetic Results From a Phase 1, Multidose, Open-Label Study
AUTHOR(S)

Melissa DelBello,1 Liming Zhang,2 Ishani Landry,2 David McDonnell,3 Lara Finlayson2

View poster
Bipolar Disorder